Roche's Failed Schizophrenia Drug Just Aced a Trial for a Rare Disease
A schizophrenia drug that flopped at Roche just swept every endpoint in a pivotal trial for a painful sun-sensitivity disorder with zero approved treatments. Disc Medicine's bitopertin could become the first therapy ever for erythropoietic protoporphyria.
Imagine being allergic to sunlight. Not in a vampire-movie way, but in a "ten minutes outside and your skin feels like it's on fire" way. That's life with erythropoietic protoporphyria, or EPP: a rare genetic disorder that turns ordinary daylight into a source of searing, unpredictable pain.
While SCENESSE (afamelanotide) was approved by the FDA in 2019 for adult EPP patients, treatment options remain extremely limited. Patients largely manage by hiding indoors, layering on protective clothing, and hoping for cloudy days. For decades, the pharma industry mostly shrugged.
That changed on October 19, 2026, when Disc Medicine announced that its drug bitopertin crushed every endpoint in the pivotal Phase 3 APOLLO trial. The kicker? This molecule was originally built for schizophrenia. It failed there. And now it might become a transformative therapy for one of the most overlooked diseases in medicine.
A Drug Gets a Second Life
Bitopertin has had quite the career arc. Roche developed it years ago as a treatment for schizophrenia, aiming to boost a brain chemical called glycine by blocking its recycling transporter (GlyT1). The idea was solid in theory: more glycine, better brain signaling, fewer negative symptoms. In practice, the late-stage schizophrenia program fizzled.
But someone noticed something interesting about how the drug worked. That same glycine transporter doesn't just operate in the brain. It also feeds glycine to developing red blood cells, where glycine is the raw material for making heme (the iron-carrying part of hemoglobin). In EPP patients, the heme production line is broken, and a toxic byproduct called protoporphyrin IX (PPIX) piles up in the blood and skin. When sunlight hits that PPIX, it triggers brutal phototoxic reactions.
Disc Medicine's insight was beautifully simple: if you limit the glycine supply, you slow down the whole heme assembly line and reduce PPIX buildup. Think of it like turning down the faucet to prevent a bathtub from overflowing. The drug doesn't fix the broken drain, but it stops the flooding.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The APOLLO trial enrolled 183 patients across the U.S., Canada, Europe, and Australia, including adults and adolescents 12 and older. Half received 60 mg of bitopertin once daily; half got placebo. The study ran for six months.
Both co-primary endpoints hit with statistical significance. Patients on bitopertin saw a 41.4% reduction in blood PPIX levels compared to placebo (p<0.0001). That's the biomarker showing the drug is doing its job at the molecular level.
But here's the endpoint that actually matters to patients: those taking bitopertin gained an extra 12.2 hours per month of pain-free time in light during month six (p=0.0010). Twelve more hours a month might not sound revolutionary on paper. For someone who has spent their entire life rationing minutes of sunlight like a precious resource, it's a different world.
Every secondary endpoint cleared too. The rate of phototoxic reactions dropped significantly (p<0.0001). Cumulative pain-free time in light over the full six months improved (p<0.0001). Adults could tolerate more sunlight before symptoms appeared (p=0.0077). And patient-reported quality of life scores improved across the board (p<0.0001 on both global impression measures).
What 41% Less PPIX Actually Feels Like
A 41.4% reduction in a biomarker is the kind of thing that makes scientists nod approvingly. But what does it translate to in real life?
EPP patients live on a razor's edge. A quick walk to the car, a few minutes at a bus stop, eating lunch near a window: any of these can trigger episodes of deep, burning pain that can last for hours or even days. The pain isn't on the surface; patients describe it as feeling like their blood is boiling under their skin.
Cutting PPIX by roughly 40% doesn't eliminate the problem. It widens the margin. Patients can likely spend more time outdoors before hitting their threshold. Reactions may become less frequent and less intense. For kids who've never been able to play outside at recess, or adults who've structured entire careers around avoiding windows, the psychological relief alone is enormous.
The disease affects somewhere between 1 in 17,000 and 1 in 100,000 people, depending on which study you trust. That wide range hints at massive underdiagnosis; the average patient waits over a decade for a correct diagnosis. Many doctors have simply never heard of it.
The Safety Question (and the One Number That Raised Eyebrows)
Bitopertin was generally well tolerated, but one adverse event stood out: dizziness hit 50% of patients in the treatment group. That's a big number. Disc Medicine described the episodes as mild or moderate and mostly transient, which tracks with the drug's origin as a brain-active compound. GlyT1 inhibition in the central nervous system was the whole point of the original schizophrenia program, after all.
Whether that dizziness rate gives the FDA pause will depend on severity, duration, and how regulators weigh it against the very limited existing options. For a disease with so few approved treatments, the bar for tolerability is different than it would be for, say, a fifth cholesterol drug.
Already at the FDA's Door
Disc Medicine isn't waiting around. The company actually filed its NDA in September 2025, seeking accelerated approval based on the PPIX biomarker from earlier data. The APOLLO trial serves as the confirmatory study that the FDA typically requires under accelerated approval.
Even better, Disc received an FDA Commissioner's National Priority Voucher, which is designed to compress the review timeline to just one or two months from NDA acceptance. If everything lines up, bitopertin could reach patients remarkably fast by pharma standards.
Wall Street Was Already on Board
Analysts had been positioning for this catalyst. Heading into the readout, price targets from major banks clustered between $86 and $128, with firms like Jefferies, H.C. Wainwright, and Stifel all maintaining Buy ratings. The consensus hovered around $102 to $110.
The bearish case centered on competition from dersimelagon (another EPP candidate) and questions about whether bitopertin's earlier data justified the valuation. But a clean sweep of every primary and secondary endpoint in a pivotal trial tends to quiet skeptics in a hurry.
The Bigger Picture
Bitopertin's story is a reminder that drug development isn't always linear. A molecule designed for one of the most common psychiatric conditions on earth ended up being the potential savior for one of the rarest skin diseases. Roche's failure became Disc Medicine's opportunity.
For EPP patients, the significance is hard to overstate. These are people who have been told for their entire lives that nothing can help them, that they should just stay inside. If bitopertin gets approved, it won't just be a new drug. It'll be a major new treatment option. And sometimes, that's the only number that really matters.
Clinical & Regulatory
4 min read
Gilead Just Crashed the Biggest Party in Gastroenterology
Gilead's ulcerative colitis pill posted mid-stage results that beat Wall Street expectations, with remission rates nearly four times higher than placebo. The HIV giant just served notice to AbbVie, Takeda, and every other player in the $25 billion IBD market.
